FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1810885877> ?p ?o ?g. }

• W1810885877 endingPage "1264" @default.
• W1810885877 startingPage "1256" @default.
• W1810885877 abstract "PURPOSE To identify a biologically favorable and unfavorable subset of patients with Evans stage III neuroblastoma and to determine whether treatment stratification would improve the event-free survival (EFS) for high-risk patients and maintain excellent EFS for the lower-risk patients. PATIENTS AND METHODS Risk stratification was performed by age, MYCN gene copy number, Shimada histopathologic classification, and serum ferritin level. Lower-risk patients were treated on the less intensive Children's Cancer Group (CCG)-3881, whereas high-risk patients were treated on CCG-3891, which included more intensive multimodality therapy and, in some cases, autologous bone marrow transplantation (ABMT). RESULTS Of 228 Evans stage III patients entered onto the study, 92% also met the definition of International Neuroblastoma Staging System (INSS) stage 3. One hundred forty-three patients met the lower-risk criteria, which included 89 patients less than 1 year of age and 54 patients 1 year of age or greater, and favorable biology, whereas 85 patients were 1 year of age or greater and biologically unfavorable. Biologically unfavorable patients 1 year of age or greater who underwent gross surgical resection had improved survival, whereas the outcome of infants or biologically favorable older patients did not change according to resection. The EFS rate at 4 years was 100% for the patients with favorable biology of any age, 90% for those less than 1 year of age but with at least one unfavorable characteristic, and 54% for Evans stage III patients 1 year of age or greater with unfavorable biology. Age, ferritin level, MYCN copy number, Shimada histopathology, primary site, and intraspinal extension were significant univariate prognostic factors for all patients, but only MYCN copy number and age were independent factors in multivariate analyses. CONCLUSION The excellent survival of the biologically favorable group and the historically improved EFS of the biologically unfavorable group suggest that biologic staging should be used to define the prognosis and treatment of stage III neuroblastoma." @default.
• W1810885877 created "2016-06-24" @default.
• W1810885877 creator A5004950779 @default.
• W1810885877 creator A5008628156 @default.
• W1810885877 creator A5009745981 @default.
• W1810885877 creator A5017840054 @default.
• W1810885877 creator A5021003209 @default.
• W1810885877 creator A5041065705 @default.
• W1810885877 creator A5046710077 @default.
• W1810885877 creator A5060036184 @default.
• W1810885877 creator A5061519996 @default.
• W1810885877 creator A5067145358 @default.
• W1810885877 creator A5068311191 @default.
• W1810885877 creator A5081260490 @default.
• W1810885877 date "1998-04-01" @default.
• W1810885877 modified "2023-10-09" @default.
• W1810885877 title "Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study." @default.
• W1810885877 cites W1580788756 @default.
• W1810885877 cites W1844869739 @default.
• W1810885877 cites W1854022682 @default.
• W1810885877 cites W1877527541 @default.
• W1810885877 cites W1926885922 @default.
• W1810885877 cites W1979300931 @default.
• W1810885877 cites W2008501462 @default.
• W1810885877 cites W2018075150 @default.
• W1810885877 cites W2023541196 @default.
• W1810885877 cites W2024280594 @default.
• W1810885877 cites W2032458997 @default.
• W1810885877 cites W2052557404 @default.
• W1810885877 cites W2080261058 @default.
• W1810885877 cites W2089013060 @default.
• W1810885877 cites W2096398040 @default.
• W1810885877 cites W2132881315 @default.
• W1810885877 cites W2147644006 @default.
• W1810885877 cites W2157341748 @default.
• W1810885877 cites W2224014377 @default.
• W1810885877 cites W2263175166 @default.
• W1810885877 cites W2267436557 @default.
• W1810885877 cites W2330923897 @default.
• W1810885877 cites W2472581739 @default.
• W1810885877 doi "https://doi.org/10.1200/jco.1998.16.4.1256" @default.
• W1810885877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9552023" @default.
• W1810885877 hasPublicationYear "1998" @default.
• W1810885877 type Work @default.
• W1810885877 sameAs 1810885877 @default.
• W1810885877 citedByCount "209" @default.
• W1810885877 countsByYear W18108858772012 @default.
• W1810885877 countsByYear W18108858772013 @default.
• W1810885877 countsByYear W18108858772014 @default.
• W1810885877 countsByYear W18108858772015 @default.
• W1810885877 countsByYear W18108858772016 @default.
• W1810885877 countsByYear W18108858772017 @default.
• W1810885877 countsByYear W18108858772018 @default.
• W1810885877 countsByYear W18108858772019 @default.
• W1810885877 countsByYear W18108858772020 @default.
• W1810885877 countsByYear W18108858772021 @default.
• W1810885877 countsByYear W18108858772022 @default.
• W1810885877 countsByYear W18108858772023 @default.
• W1810885877 crossrefType "journal-article" @default.
• W1810885877 hasAuthorship W1810885877A5004950779 @default.
• W1810885877 hasAuthorship W1810885877A5008628156 @default.
• W1810885877 hasAuthorship W1810885877A5009745981 @default.
• W1810885877 hasAuthorship W1810885877A5017840054 @default.
• W1810885877 hasAuthorship W1810885877A5021003209 @default.
• W1810885877 hasAuthorship W1810885877A5041065705 @default.
• W1810885877 hasAuthorship W1810885877A5046710077 @default.
• W1810885877 hasAuthorship W1810885877A5060036184 @default.
• W1810885877 hasAuthorship W1810885877A5061519996 @default.
• W1810885877 hasAuthorship W1810885877A5067145358 @default.
• W1810885877 hasAuthorship W1810885877A5068311191 @default.
• W1810885877 hasAuthorship W1810885877A5081260490 @default.
• W1810885877 hasConcept C121608353 @default.
• W1810885877 hasConcept C126322002 @default.
• W1810885877 hasConcept C141071460 @default.
• W1810885877 hasConcept C143998085 @default.
• W1810885877 hasConcept C146357865 @default.
• W1810885877 hasConcept C151730666 @default.
• W1810885877 hasConcept C2776715637 @default.
• W1810885877 hasConcept C54355233 @default.
• W1810885877 hasConcept C71924100 @default.
• W1810885877 hasConcept C81885089 @default.
• W1810885877 hasConcept C86803240 @default.
• W1810885877 hasConceptScore W1810885877C121608353 @default.
• W1810885877 hasConceptScore W1810885877C126322002 @default.
• W1810885877 hasConceptScore W1810885877C141071460 @default.
• W1810885877 hasConceptScore W1810885877C143998085 @default.
• W1810885877 hasConceptScore W1810885877C146357865 @default.
• W1810885877 hasConceptScore W1810885877C151730666 @default.
• W1810885877 hasConceptScore W1810885877C2776715637 @default.
• W1810885877 hasConceptScore W1810885877C54355233 @default.
• W1810885877 hasConceptScore W1810885877C71924100 @default.
• W1810885877 hasConceptScore W1810885877C81885089 @default.
• W1810885877 hasConceptScore W1810885877C86803240 @default.
• W1810885877 hasIssue "4" @default.
• W1810885877 hasLocation W18108858771 @default.
• W1810885877 hasLocation W18108858772 @default.
• W1810885877 hasOpenAccess W1810885877 @default.
• W1810885877 hasPrimaryLocation W18108858771 @default.

• next